OmniAb Inc reports results for the quarter ended June 30 - Earnings Summary
OmniAb Inc reports results for the quarter ended June 30 - Earnings Summary
OmniAb Inc OABI.OQ reported a quarterly adjusted loss of 5 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -15 cents. The mean expectation of seven analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -14 cents to -10 cents per share.
Revenue rose 244.2% to $13.42 million from a year ago; analysts expected $4.69 million.
OmniAb Inc's reported EPS for the quarter was a loss of 5 cents.
The company reported a quarterly loss of $5.86 million.
OmniAb Inc shares had fallen by 8.9% this quarter and gained 21.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 4.3% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for OmniAb Inc is $8.00, about 72% above its last closing price of $2.24
This summary was machine generated from LSEG data August 7 at 01:49 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.12 | -0.05 | Beat |
Mar. 31 2026 | -0.10 | -0.06 | Beat |
Dec. 31 2025 | -0.09 | -0.11 | Missed |
Sep. 30 2025 | -0.14 | -0.14 | Met |
Recent news on OmniAB
See all newsU.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
OmniAb rises on drug discovery deal with Lilly worth up to $370 million
U.S. STOCKS ON THE MOVE - KBR, Vista Energy, Fulcrum Therapeutics
OmniAb rises on drug discovery deal with Lilly worth up to $370 mln